Evidence map›Paper›PMID 41286569›Full record

ArticleClinical endocrinology2026

Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight.

Niki Jalava, Terhi J Heino, Pirjo Nuutila, Kirsi A Virtanen, Kaisa K Ivaska

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Niki JalavaInstitute of Biomedicine, University of Turku, Turku, Southwest Finland, Finland.ORCID https://orcid.org/0000-0002-2475-7898
Terhi J HeinoInstitute of Biomedicine, University of Turku, Turku, Southwest Finland, Finland.ORCID https://orcid.org/0000-0003-2274-6834
Pirjo NuutilaTurku PET Centre, University of Turku, Turku, Southwest Finland, Finland.ORCID https://orcid.org/0000-0001-9597-338X
Kirsi A VirtanenTurku PET Centre, University of Turku, Turku, Southwest Finland, Finland.ORCID https://orcid.org/0000-0001-6183-4525
Kaisa K IvaskaInstitute of Biomedicine, University of Turku, Turku, Southwest Finland, Finland.ORCID https://orcid.org/0000-0001-7482-7623

Funding

This study was supported by grants from the Research Council of Finland (grant# 325498 to K.K.I., #335446 to K.A.V.), Finnish Diabetes Research Foundation (K.A.V.), the Sigrid Juselius Foundation (K.A.V.), Government Research Funds (K.A.V.), Instrumentarium Research Fund (N.J.), Diabetes Wellness Finland (K.K.I.), Laboratoriolääketieteen edistämissäätiö (K.K.I.), University of Turku Graduate School (N.J.).
6 · The paper itself

Abstract

objectiveBone is a target for diabetic complications, but the impact of metabolic changes on bone metabolism is less understood. Bones participate in energy metabolism by via secreted osteokines. Glucose ingestion reduces bone resorption, but the effects on osteokines remain unknown. Further, it is not known whether the response is altered in obesity. The objective of the study was to compare responses in circulating levels of osteokines to glucose ingestion between participants with normal weight (BMI < 26 kg/m MEASUREMENTS: C-terminal telopeptide of collagen I (b-CTX-I), total osteocalcin (OC), sclerostin, fibroblast growth-factor 23 (cFGF23), uncarboxylated OC, and lipocalin 2 (LCN2) at baseline and after 2 h oral glucose tolerance test (OGTT).

resultsOGTT resulted in a significant decrease in bone resorption, median decrease in b-CTX-I was 42% (p < 0.0001) in both groups. Osteokine levels were modestly but statistically significantly decreased, OC decreased by 11% (p < 0.0001) and FGF23 by 14% (p = 0.007) in both groups, while uncarboxylated OC decreased by 1.2% (p < 0.0001) and sclerostin by 7.8% (p = 0.032) only in participants with obesity. Although the differences in responses between the groups were not statistically significant, we observed a tendency for less pronounced effect on b-CTX-I (p = 0.052) and a greater effect on OC (p = 0.051) in participants with obesity compared to normal weight.

conclusionOsteokines respond rapidly to oral glucose regardless of body weight. Orally-administered glucose affects not only bone turnover but can also suppress bone endocrine functions. Furthermore, obesity may influence the effect of oral glucose on circulating levels of bone turnover markers.

Indexed as

Body WeightBone and BonesGlucoseAdaptor Proteins, Signal TransducingAdministration, OralAdultBone Morphogenetic ProteinsBone ResorptionCollagen Type IFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGlucose Tolerance TestHumansMaleMiddle AgedAdaptor Proteins, Signal TransducingBone Morphogenetic ProteinsCollagen Type Icollagen type I trimeric cross-linked peptideFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsGlucoseOsteocalcinPeptidesSOST protein, humanbonebone endocrine functionsobesityoral glucose tolerance testosteokine

Identifiers

PMID41286569
PMCPMC12757891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.